Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Histogenics Cp (HSGX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 78,021
  • Shares Outstanding, K 28,790
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,410 K
  • 36-Month Beta 1.51
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.19
  • Number of Estimates 2
  • High Estimate -0.14
  • Low Estimate -0.24
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +17.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.12 +24.53%
on 07/27/18
2.83 -6.71%
on 08/14/18
+0.20 (+8.20%)
since 07/17/18
3-Month
2.06 +28.16%
on 05/18/18
3.05 -13.44%
on 06/15/18
+0.57 (+27.54%)
since 05/17/18
52-Week
1.60 +65.00%
on 08/23/17
3.35 -21.19%
on 03/15/18
+0.87 (+49.15%)
since 08/17/17

Most Recent Stories

More News
Histogenics Sees Hammer Chart Pattern: Time to Buy?

Histogenics has been struggling lately, but the selling pressure may be coming to an end soon.

HSGX : 2.64 (-2.58%)
Histogenics Corp. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Histogenics Corp. (NASDAQ: ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 8:30 AM Eastern Time.

HSGX : 2.64 (-2.58%)
Histogenics Corporation Announces Second Quarter 2018 Financial and Operating Results

â?' Top-line Superiority Data from NeoCart Phase 3 Clinical Trial on Track for Third Quarter of 2018 â?'

HSGX : 2.64 (-2.58%)
Histogenics Corporation Appoints E. Lynne Kelley, M.D., FACS As Chief Medical Officer

Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies (RCTs) that may offer rapid-onset pain relief and restored function, today announced the appointment...

HSGX : 2.64 (-2.58%)
Histogenics Corporation to Host Investor Day on June 19, 2018

Histogenics Corporation (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Histogenics will host its first...

HSGX : 2.64 (-2.58%)
Histogenics Corporation Announces First Quarter 2018 Financial and Operating Results

â?' Top-line Superiority Data from NeoCart Phase 3 Clinical Trial and Potential Biologics License Application Submission on Track for Third Quarter of 2018 â?'

HSGX : 2.64 (-2.58%)
Histogenics Corporation to Report First Quarter 2018 Financial Results on May 10, 2018

Histogenics Corporation (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced it will report its first quarter...

HSGX : 2.64 (-2.58%)
Histogenics Corporation Announces the Appointment of Susan Washer to Its Board of Directors

Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies (RCTs) that may offer rapid-onset pain relief and restored function, today announced the appointment...

HSGX : 2.64 (-2.58%)
Histogenics Corporation to Present at Upcoming Investor Conferences

Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Company Management...

HSGX : 2.64 (-2.58%)
Histogenics Corporation to Present at Needham & Company's 17th Annual Healthcare Conference

Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced that Adam Gridley,...

HSGX : 2.64 (-2.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade HSGX with:

Business Summary

Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts....

See More

Key Turning Points

2nd Resistance Point 2.74
1st Resistance Point 2.69
Last Price 2.64
1st Support Level 2.60
2nd Support Level 2.56

See More

52-Week High 3.35
Fibonacci 61.8% 2.68
Last Price 2.64
Fibonacci 50% 2.47
Fibonacci 38.2% 2.27
52-Week Low 1.60

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar